Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
BLFS Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reflects a mixed outlook: declining gross margins due to product mix and manufacturing issues, but a positive net income and ongoing product development. The Q&A highlights potential future benefits from new products and market expansion but also indicates current challenges with margins and no immediate synergies from recent agreements. The guidance for 2026 is cautiously optimistic but lacks strong short-term catalysts, resulting in a neutral sentiment for the stock price.
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance with a 15% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating confidence in future growth. Despite the absence of details on operational updates and shareholder returns, the positive financial metrics, increased cash flow, and optimistic guidance suggest a favorable outlook. The lack of concerning insights from the Q&A further supports a positive sentiment.
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reflects positive sentiment, with raised revenue guidance and improved financial metrics such as GAAP net income and adjusted EBITDA. Despite increased expenses, the company demonstrates strong growth and financial health. The Q&A section supports this with optimistic outlooks for 2026 and no major concerns from analysts. While there are some uncertainties, like the government shutdown, they are already accounted for in the guidance. The focus on growth through commercial customers and the stable funding environment further boosts confidence, indicating a likely positive stock price movement.
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary shows strong financial performance, with a 33% revenue growth in cell processing and improved EBITDA margin. The acquisition of PanTHERA enhances the company's capabilities. Despite increased operating expenses due to acquisition costs, the adjusted operating loss improved. The Q&A section revealed confidence in future revenue, cross-selling opportunities, and product interest. However, the market cap is unavailable, but given the positive trends and strategic positioning, a positive stock price movement (2% to 8%) is anticipated.
BLFS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
